AMRI selects compound for advanced preclinical tests in treatment of IBS AMRI today announced selecting a compound from its proprietary research program for the treating irritable bowel syndrome for advanced preclinical assessment, with the goal of submitting an Investigational New Medication Software with the U.S. Food and Medication Administration in 2011. This approach is definitely differentiated from the prevailing course of 5-HT3 receptor antagonists that completely block receptor function. Related StoriesNegative body image significantly increases weight problems risk among adolescentsAustralian experts define key characteristics of metabolically healthy obeseTwo Duke obesity specialists' in the November issue of Health AffairsPending favorable results in toxicity and security pharmacology testing content articles appear, AMRI estimates that it’ll submit an IND for this compound in the 1st half of 2011.Of these abnormalities, 38 were trisomy 21, 10 were trisomy 18, 6 were trisomy 13, 3 had been 45,X, 3 had been marker chromosomes, 2 had been unbalanced translocations, 2 had been balanced translocations, and 1 each was deletion 7p, deletion/duplication 5p, 1q41 deletion, and isochromosome Yp. Trisomy 21 was recognized in 38 of 15,841 women, for a prevalence of just one 1 in 417. Principal Analysis The AUC for trisomy 21 was 0.999 for cfDNA testing and 0.958 for regular screening . Of the 38 participants with trisomy 21 with an outcome on cfDNA testing, cfDNA identified all 38 instances, for a sensitivity of 100 percent . Regular screening identified 30 of 38 cases as positive, a sensitivity of 78.9 percent . There have been 9 fake positives among the 15,803 ladies in the cfDNA-testing group without trisomy 21, for a false positive price of 0.06 percent .